Atlas Trials

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

Clinical trial NCT03585686 · UNKNOWN

Trial details

NCT number
NCT03585686
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Langerhans Cell Histiocytosis
Start date
2018-06-26
Primary completion
2023-04-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.